Kodiak Sciences Inc. is a biopharmaceutical company that develops and sells treatments for retinal diseases, such as wet age-related macular degeneration. The company's lead product candidate is KSI-301, which is currently in Phase IIb/III clinical study. Other product candidates include KSI-501 and KSI-601, both of which are still in preclinical stages.